TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06704334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve electrical stimulation treatment
Description: Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve electrical stimulation treatment
Description: Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve electrical stimulation treatment
Description: Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A injection
Description: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A injection
Description: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo leaf dropping pill
Description: oral
Study: NCT06727890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danshen Dripping Pill
Description: Danshen Dripping Pill, 10 pills once, three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 10 pills once, three times a day
Study: NCT06729528

Intervention type: DIAGNOSTIC_TEST
Intervention: The PePCI and ManTIS scores
Description: The PePCI and ManTIS scores have been developed to predict the indication for whole-body CT in pediatric cases presenting to the emergency department with trauma. These scores help reduce unnecessary radiation exposure in pediatric trauma cases.
Study: NCT06728553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX101
Description: One 2 mg sublingual tablet of MTX101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sublingual tablet of placebo
Study: NCT06729827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypotension prediction Index - HPI
Description: Patients in the HPI group, in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA) with ClearSight non-invasive hemodynamic monitoring and with the HPI software enabled.~The patients will be treated with a bolus of norepinephrine 5 mcg each time that HPI is 85 or higher.
Study: NCT06729671

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule
Description: Bifidobacterium longum APC1472 capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin
Study: NCT06727877

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.
Description: The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.~The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.
Description: The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.~The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns.
Study: NCT06729567

Intervention type: OTHER
Intervention: Spinal block level analysis
Description: Relation of the dose of hyperbaric bupivacaine to resulting spinal block level is to be assessed. Conventional dose cases (more than 9mg and less than 13mg) will be included in analysis.

Intervention type: OTHER
Intervention: data collection
Description: Intervention is to acquire and analyse anonymous perioperative data. After identification of the eligible cases, statistical analysis will be performed.
Study: NCT06729840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Vitamin D , botox , tramcinolone intralesionally injected in keloid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Vitamin D , botox , tramcinolone intralesionally injected in keloid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Vitamin D , botox , tramcinolone intralesionally injected in keloid
Study: NCT06728670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid Intravenous Infusion
Description: A slow intravenous infusion of 1g TXA was administered at a rate of about 1ml/min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXA intramuscular injection
Description: 5ml intramuscular injections of TXA with twice, each injection time no more than 30 seconds, the injection site was selected as triangle
Study: NCT06729047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: patients will receive placebo (normal saline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: patients will receive ketorolac (0.5 mg/kg)
Study: NCT06727838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablets
Description: HRS-7535 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended-release Tablets
Description: Metformin Hydrochloride Extended-release Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Tablets
Description: Metformin Hydrochloride Tablets.
Study: NCT06728839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1L PEG + 50g magnesium sulfate
Description: Subjects in Group A will use a regimen combining magnesium sulfate and polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. 1 litter of polyethylene glycol is taken at 8pm the day before the colonoscopy and 50 gram of magnesium sulfate is taken 4-6 hours before the colonoscopy, and then drink 2000 ml of water within 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3L PEG
Description: Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4L PEG
Description: Subjects in Group C will use a regimen with 4L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 4 liters of polyethylene glycol solution is taken in split dosing, with 2 liters taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
Study: NCT06729086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sedation using propofol
Description: The different complications studied will be for example respiratory, neurologic and cardiac based on several clinical and biological parameters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedation using sevoflurane
Description: The differents complications studied will be for example respiratory, neurologic and cardiac based on severl clinical and biological parameters.
Study: NCT06729034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban (Eliquis)
Description: 5 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo twice daily
Study: NCT05939856

Intervention type: OTHER
Group type: OTHER
Intervention: Lymph node dissection before bladder resection
Description: Lymph node dissection before bladder resection

Intervention type: OTHER
Group type: OTHER
Intervention: Lymph node dissection after bladder resection
Description: Lymph node dissection after bladder resection
Study: NCT05728866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VR immersive therapy
Description: Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
Study: NCT05621889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual group speech therapy intervention guided by a patient partner
Description: virtual group speech therapy intervention guided by a patient partner
Study: NCT06471439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single leg exercise intervantion in COPD
Description: single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single leg exercise intervantion in COPD
Description: single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single leg exercise intervantion in COPD
Description: single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training
Study: NCT05341024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers
Description: The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
Study: NCT06506123

Intervention type: DEVICE
Intervention: Artificial Intelligence Detection and Classification of Patient-Ventilator Dyssynchronies
Description: Machine learning algorithm to detect and classify patient-ventilator dyssynchronies, which is integrated in the mechanical ventilator (Fleximag Max, Magnamed, Brazil).
Study: NCT05110508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Based Behavioral Intervention for Physical Activity
Description: Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
Study: NCT05333497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument
Description: Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the fourth generation of low-frequency acupoint electric stimulation therapy instrument
Description: In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
Study: NCT06200532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOOTSAK (FOOTwear self-assessment kit)
Description: FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. It includes measuring tools (an internal footwear length gauge, scale dividers for measuring internal footwear width, a slide rule for measuring foot length and width, a ruler and magnifying glass for reading off measurements) and instructional materials (booklet instructions and video materials)
Study: NCT05417776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Dotarem will be administered during MRI portion of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Dotarem will be administered during MRI portion of study.
Study: NCT04752410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Brachial Plexus Block
Description: It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
Study: NCT06253078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol dose 0.4mg/Kg
Description: The initial dose of ciprofol was 0.4mg/Kg for induction in this group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol dose 0.4mg/Kg
Description: The initial dose of ciprofol was 0.4mg/Kg for induction in this group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol dose 0.3mg/Kg
Description: The initial dose of ciprofol was 0.3mg/Kg for induction in this group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol dose 0.3mg/Kg
Description: The initial dose of ciprofol was 0.3mg/Kg for induction in this group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol dose 0.2mg/Kg
Description: The initial dose of ciprofol was 0.2mg/Kg for induction in this group.
Study: NCT05193903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: The participants in the intervention group receive two interactive simulations in addition to a general text module that provides sequential, animated information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text
Description: The participants in the control group receive two text-based information in addition to a general text module that provides information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.~Both conditions ensure the provision of a level of knowledge that at least corresponds to standard care.
Study: NCT04828837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bubble PEP
Description: Using the bubble positive expiratory pressure (Bubble PEP) for breathing training of inpatients with COPD. The training course for one day of three times. Every time needs about 20 mins. Huff and cough after the breathing training the end.
Study: NCT05139251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovering from Intimate partner violence through Strengths and Empowerment (RISE)
Description: RISE intervention will be implemented for a period of 4 weeks at the beginning of the program. Four components/modules of the RISE intervention which includes a) education on health effects of violence, b) improving coping and self-care, c) enhancing social support, and d) addressing sexual violence will be used. Toward the beginning of each session the participant will complete a brief survey including a 10-item general self-efficacy scale to be graphed and discussed together to provide more immediate feedback to women about their progress, and at times, inform module selection. At the conclusion of each RISE session, women are asked to set a goal related to the topic in consultation with the clinician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePALS
Description: Participants and their children will then receive 6 weekly sessions of ePALS. The ePALS sessions include rapport building, recognizing and understanding children's signals, contingently responding to signals, labeling objects and actions, learning book reading strategies, maintaining children's focus of attention, helping children with self-regulation, and language scaffolding techniques. Each parent will have a personal parenting coach who remotely supports their progress through the program.~After a parent views a PALS coaching session, they will videotape themselves trying the strategy for that week with their child. Then their coach sets up a zoom call and together they talk about the PALS strategy and view the video. The coach facilitates parental appraisal of their behavior and discuss what they thought worked with their child and what they want to do differently.
Study: NCT06421155

Intervention type: OTHER
Group type: OTHER
Intervention: MRF with neurocognative studies
Description: Magnetic Resonance Imaging is used to assess the risk of neurocognitive side effects in pediatric and AYA patients with acute leukemia receiving chemotherapy and participants will also be asked to complete a neurocognitive battery designed by Cogstate and administered on iPad in a simple gaming format
Study: NCT05617664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin 120 mcg oral tablets
Description: treatment for three months then will stop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 25 MG Oral Tablet, Extended Release
Description: treatment for three months then will stop

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral therapy alone
Description: no medications will be given to the patient
Study: NCT04387305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.
Study: NCT04782440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitaton
Description: Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients will be given a home-based exercise program without telerehabilitation supervision